http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Chunping Yu,Yi Zhang,Ning Wang,Wensu Wei,Ke Cao,Qun Zhang,Peiying Ma,Dan Xie,Pei Wu,Biao Liu,Jiahao Liu,Wei Xiang,Xing Hu,Xuewen Liu,Jianfei Xie,Jin Tang,Zhi Long,Long Wang,Hongliang Zeng,Jianye Liu 한국생체재료학회 2022 생체재료학회지 Vol.26 No.1
Background: Circular RNAs (circRNAs) have important functions in many fields of cancer biology. In particular, we previously reported that the oncogenic circRNA, circPRMT5, has a major role in bladder cancer progression. Therapy based on circRNAs have good prospects as anticancer strategies. While anti-circRNAs are emerging as therapeutics, the specific in vivo delivery of anti-circRNAs into cancer cells has not been reported and remains challenging. Methods: Synthesized chrysotile nanotubes (SCNTs) with a relatively uniform length (~ 200 nm) have been designed to deliver an siRNA against the oncogenic circPRMT5 (si-circPRMT5) inhibit circPRMT5. In addition, the antitumor effects and safety evaluation of SCNTs/si-circPRMT5 was assessed with a series of in vitro and in vivo assays. Results: The results showed that SCNTs/si-circPRMT5 nanomaterials prolong si-circPRMT5’s half-life in circulation, enhance its specific uptake by tumor cells, and maximize the silencing efficiency of circPRMT5. In vitro, SCNTs encapsulating si-circPRMT5 could inhibit bladder cancer cell growth and progression. In vivo, SCNTs/si-circPRMT5 inhibited growth and metastasis in three bladder tumor models (a subcutaneous model, a tail vein injection lung metastatic model, and an in situ model) without obvious toxicities. Mechanistic study showed that SCNTs/sicircPRMT5 regulated the miR-30c/SNAIL1/E-adherin axis, inhibiting bladder cancer growth and progression. Conclusion: The results highlight the potential therapeutic utility of SCNTs/si-circPRMT5 to deliver si-circPRMT5 to treat bladder cancer.
Fabrication of High-Strength Mg–Gd–Nd–Zn–Sn–Zr Alloy via Extrusion and Aging
Yan Zehua,Yu Yandong,Qian Jiahao,Luo Junting,Sang Yanchao 대한금속·재료학회 2021 METALS AND MATERIALS International Vol.27 No.10
A high-strength Mg–9Gd–3Nd–1Zn–1Sn–0.5Zr (wt%) alloy bar was successfully fabricated by extrusion and followingaging two-steps processes, during which the alloy′s microstructures were determined to investigate the refinement mechanismduring extrusion and to reveal the morphology precipitation behavior of the as-extruded alloy after aging. Based on thecharacterization of the mechanical properties, the strengthening mechanism of the alloy under different treatment processeshad been discussed. Our results showed that the greater the extent of extrusion, the finer the grains and eutectic phase, andcrushing and dynamic recrystallization are the refinement mechanisms of the alloy in narrow-zone. After peak-aged treatmentat 200 °C, a large number of spherical β′ phase and lamellar precipitated phase had been observed, which replacesthe amorphous β" phase of the alloy was under-aged. The ultimate tensile strength, yield strength, and elongation were462.12 MPa, 391.97 MPa, and 4.2% respectively, and the increase number of the β′ phase and long-period stacking ordered(LPSO) phase were the reason why the strength of the alloy reached the highest value. At the over-aging stage (96 h), thesize of the lamellar precipitates and the LPSO was larger than that of the peak-aged, and the spherical β′ phase appeared inpeak-aging stage decreased significantly, which reduced its performance.
Yanfei Zhu,Hang Liu,Chuanjiang Li,Jiahao Yu 제어·로봇·시스템학회 2022 International Journal of Control, Automation, and Vol.20 No.11
This paper is concerned with the consensus and security of leader-follower multi-agent systems with time-varying topology, where each follower’s sensor-to-controller channel and controller-to-actuator channel are subject to unknown but bounded (UBB) random deception attacks. A novel set-membership estimation and control framework is presented to realize system consensus, input-to-state stability and security performance, in which each controller receives arbitrary estimates from itself and neighbor set-membership estimators. Based on the Lyapunov functional and stochastic control method, a sufficient condition on the existence of estimators and controllers is derived. Then, a convex optimization algorithm is established to deal with the proposed framework. Finally, the effectiveness of the method is verified by numerical simulation.
Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugate
Xiang Wei,Peng Yongbo,Zeng Hongliang,Yu Chunping,Zhang Qun,Liu Biao,Liu Jiahao,Hu Xing,Wei Wensu,Deng Minhua,Wang Ning,Liu Xuewen,Xie Jianfei,Hou Weibin,Tang Jin,Long Zhi,Wang Long,Liu Jianye 한국생체재료학회 2023 생체재료학회지 Vol.27 No.00
Gemcitabine (GEM) is one of the first-line chemotherapies for bladder cancer (BC), but the GEMs cannot recognize cancer cells and have a low long-term response rate and high recurrence rate with side effects during the treatment of BC. Targeted transport of GEMs to mediate cytotoxicity to tumor and avoid the systemic side effects remains a challenge in the treatment of BC.Based on a firstly confirmed biomarker in BC-protein tyrosine kinase 7 (PTK7), which is overexpressed on the cell membrane surface in BC cells, a novel targeting system protein tyrosine kinase 7 aptamer-Gemcitabine conjugate (PTK7-GEMs) was designed and synthesized using a specific PTK7 aptamer and GEM through auto-synthesis method to deliver GEM against BC. In addition, the antitumor effects and safety evaluation of PTK7-GEMs was assessed with a series of in vitro and in vivo assays.PTK7-GEMs can specifically bind and enter to BC cells dependent on the expression levels of PTK7 and via the macropinocytosis pathway, which induced cytotoxicity after GEM cleavage from PTK7-GEMs respond to the intracellular phosphatase. Moreover, PTK7-GEMs showed stronger anti-tumor efficacy and excellent biosafety in three types of tumor xenograft mice models.These results demonstrated that PTK7-GEMs is a successful targeted aptamer-drug conjugates strategy (APDCs) to treat BC, which will provide new directions for the precision treatment of BC in the field of biomarker-oriented tumor targeted therapy.